8-K
filed June 11, 2026, 4:12 PM ET
ticker PBLS
CIK 0001657677
other material
confidence high
sentiment positive
materiality 0.75
Regeneron invests $75M in Parabilis at 10% discount to IPO price in concurrent private placement
Parabilis Medicines, Inc.
- Purchased 4,166,666 shares at 90% of $20 IPO price ($18/share); total $75M.
- Private placement closed June 11, 2026, alongside IPO.
- Regeneron granted piggyback registration rights on the shares.
- Charter amended to authorize 600M voting and 200M non-voting common shares, eliminate preferred.
- Transaction signals strategic backing from a major biopharma partner.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Parabilis Medicines, Inc. issued 4,166,666 shares of common stock to Regeneron Pharmaceuticals, Inc. for per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share.
- Security
- common stock
- Shares
- 4,166,666 shares
- Purchaser
- Regeneron Pharmaceuticals, Inc.
- Consideration
- per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share
Exact text from the filing
On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock. The Private Placement closed on June 11, 2026.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Parabilis Medicines, Inc.: Filed seventh amended and restated certificate of incorporation to authorize capital stock changes, eliminate references to prior series of preferred stock, and authorize undesignated preferred stock (effective 2026-06-11).
- Change
- charter amendment
- Effective
- 2026-06-11
Exact text from the filing
the Company filed its seventh amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Parabilis Medicines, Inc.: Amended and restated bylaws to establish procedures for stockholder meetings, advance notice for proposals and nominations, and conform to amended certificate (effective 2026-06-09).
- Change
- bylaw amendment
- Effective
- 2026-06-09
Exact text from the filing
the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of the effectiveness of the Registration Statement
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Parabilis Medicines, Inc. entered into Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. valued at aggregate of 4,166,666 shares at 90% of the $20.00 IPO price (effective 2026-06-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Regeneron Pharmaceuticals, Inc.
- Value
- aggregate of 4,166,666 shares at 90% of the $20.00 IPO price
- Effective
- 2026-06-09
Exact text from the filing
On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.